Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Cadila Healthcare - Divests animal health business - ICICI Securities

Posted On: 2021-05-13 16:18:45 (Time Zone: UTC)

Cadila Healthcare (Cadila) announced that it has entered into an agreement to sell its animal healthcare business in India and certain other countries to a consortium led by Multiples Alternate Asset Management. This deal has been valued at Rs29.2bn on debt free and cash free basis which translates into 4.9xEV/Sales and 19.5xEV/EBITDA on FY21 provisional numbers. We believe the valuations are decent and the deal is expected to be EPS neutral. The company will use the proceeds to retire debt in short term and to invest aggressively on biosimilars, vaccines and innovative programs over long term. We believe these investments would have longer gestation period, though COVID-19 vaccine may drive large upside in near term. Considering recent rally in stock, we downgrade it to SELL from Reduce.

- Divestment to help in reducing leverage in near term: Cadila will be selling its animal health business in India and certain other countries along with manufacturing plant at Haridwar for Rs29.2bn. This business had revenue of Rs5.1bn and EBITDA of Rs876mn in FY20 and provisional revenue and EBITDA for FY21 are Rs6bn and Rs1.5bn respectively. The company will retain its animal health business for US and EU which is currently in the development and investment phase. The money will be utilised for debt repayment in near term which will reduce the leverage significantly (net debt to fall below Rs10bn). However, the company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc. which would take few years to yield results.

- Conference call highlights: 1) Focus will be on new growth areas for next decade like specialty, vaccines, biosimilars, etc. and investments for the same would increase, 2) capital gain tax would be ~Rs2bn (25% tax rate on capital gains), hence net proceeds post tax of ~Rs27bn would be utilised for repaying debt in near term which would reduce net debt to below Rs10bn, 3) leverage can be increased in future for investments in new growth areas, 4) investment for COVID-19 vaccine is complete at the moment and additional investment may be required to augment capacity as per the demand, 5) preparing for next wave of biosimilars for FY25 onwards opportunities, 6) net fixed assets of the business sold is ~Rs1bn, 7) the deal is expected to conclude in 90 days subject to regulatory approvals.

- Valuations and risks: We have not factored in this transaction in our estimates yet pending deal conclusion and clarity on balance sheet details. The deal would be EPS neutral as interest cost will reduce with debt reduction. Considering recent rally in stock price, we downgrade Cadila to SELL from Reduce with target price of Rs490/share based on 22xFY23E EPS. Key upside risks: successful launch of COVID-19 vaccine in India with sustainable earnings potential and early resolution of Moraiya facility.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.646.95 as compared to the previous close of Rs. 629.7. The total number of shares traded during the day was 1388560 in over 22581 trades.

The stock hit an intraday high of Rs. 673.7 and intraday low of 632.8. The net turnover during the day was Rs. 904432803.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

CESC Q4FY21 Results Review Report - Loss decline, strong CF make valuation attractive - HDFC Securities

White Goods & Durables - Analysis of pressure cooker market: TTK Prestige is key beneficiary - ICICI Securities

CESC - Good earnings in a challenging environment - ICICI Securities

Somany Ceramics - Walking the talk - ICICI Securities

DB Corp - Rise in newsprint price adds to risk - ICICI Securities

CEAT - Market share ambitions remain strong - ICICI Securities

Consumer Staples & Discretionary - Worm's world view #32: Conversations with paint dealers regarding price hikes - ICICI Securities

Oil & Gas - Oil, gas & spot LNG surge to bring gains for GAIL & OIL - ICICI Securities

Asset Management Companies - Positive trends to support earnings - ICICI Securities

Q4FY21 Result Update - Lemon Tree Hotels - ICICI Direct

Q4FY21 Company Update - Globus Spirits - ICICI Direct

Q4FY21 Result Update - DB Corp - ICICI Direct

Q4FY21 Result Update - Somany Ceramics - ICICI Direct

KEC International: Company Update - Building on diversification - HDFC Securities

LIC Housing Finance - Q4 FY21 Result Update - YES Securities

Entertainment Network Ltd - Beating on solutions business - ICICI Securities

Asahi India Glass - Operating leverage, product mix aid margins - ICICI Securities

Whirlpool of India - Market leading revenue growth - ICICI Securities

Lemon Tree Hotels - Wait for recovery gets longer - ICICI Securities

LIC Housing Finance - Stupendous growth momentum; needs to shore up provisioning and capital buffer - ICICI Securities

Quant Pick - Bank of Baroda - ICICI Direct

Company Update - Amara Raja Batteries - Investor Event Outcome - ICICI Direct

Q4FY21 Result Update - Bhel - ICICI Direct

Q4FY21 Company Update - NRB Bearings - ICICI Direct

CESC - Q4FY21 First Cut - ICICI Direct

Q4FY21 Result Update - Entertainment Network India - ICICI Direct

LIC Housing Finance Results Review Report - Balance sheet beefs up; P&L to stay soft - HDFC Securities

Jubilant FoodWorks 4QFY21 Results Review Report - Missing excitement; recovery priced in - HDFC Securities

BFSI Sector Update - MFI Consultation Paper Takeaways - Incrementally positive for NBFC-MFIs - HDFC Securities

Q4FY21 Result Update - JK Cement - ICICI Direct

Q4FY21 Result Update - Minda Industries - ICICI Direct

Stock Tales - Indo Count Industries - ICICI Direct

IPO Review - Krishna Institute of Medical Sciences Ltd - ICICI Direct

Q4FY21 Company Update - Greenply Industries - ICICI Direct

IPO Review - Dodla Dairy Ltd - ICICI Direct

Lemon Tree Hotels - Q4FY21 First Cut - ICICI Direct

Jubilant Foodworks - Q4FY21 investor call takeaways - YES Securities

Greenply Industries Ltd - Q4 FY21 Result Update - YES Securities

Whirlpool of India Ltd - Q4 FY21 Result Update - YES Securities

New India Assurance Report - CoRs disappoint yet again - HDFC Securities

Maintain BUY on Kajaria Ceramics - Performance shines through; outlook bright - HDFC Securities

Retain ADD on Deccan Cement - Volume strong; high other expense dents margin - HDFC Securities

Reiterate ADD on NHPC - Lower generation impacts earnings - HDFC Securities

Maintain BUY on JK Cement - Robust volume and utilisation - HDFC Securities

Maintain BUY on DLF - Gaining traction - HDFC Securities

Maintain BUY on Capacite Infraprojects - Marginal miss - HDFC Securities

DLF Ltd - Q4 FY21 Result Update - YES Securities

Greenply Industries Ltd - Q4FY21 first cut - YES Securities

Coal India - Coal makes a comeback - ICICI Securities

Kajaria Ceramics - Q4FY21 beat largely priced in - ICICI Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020